Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulsed dye laser vs Nd:YAG laser Lesion count ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs Nd:YAG laser Time until improvement ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs Nd:YAG laser Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs intense pulsed light therapy HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs intense pulsed light therapy Participant‐assessed improvement in rosacea severity1 VAS. Scale from: 0 to 10 (0 being a poor and 10 an excellent result) · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Pulsed dye laser vs intense pulsed light therapy Proportion of participants with adverse event Pain as · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Azelaic acid vs placebo Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 401 participants | Moderate |
Pulsed dye laser vs intense pulsed light therapy Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs intense pulsed light therapy Assessment of erythema or telangiectasia 5‐point Likert scale · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 40 participants | Moderate |
Pulsed dye laser vs intense pulsed light therapy Lesion count ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs intense pulsed light therapy Time until improvement ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Pulsed dye laser vs intense pulsed light therapy Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azelaic acid vs placebo Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 5 studies · 1245 participants | High |
Azelaic acid vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical ivermectin vs placebo HRQOL DLQI and RosaQoL · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 1371 participants | High |
Topical ivermectin vs placebo Participant‐assessed improvement in rosacea severity Likert scale, good to excellent improvement · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 1371 participants | High |
Topical ivermectin vs placebo Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 1371 participants | High |
Metronidazole vs placebo Participant‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 252 participants | Moderate |
Topical ivermectin vs placebo Physician‐assessed improvement in rosacea severity Investigator's Global Assessment of clear or almost clear · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 1371 participants | High |
Topical ivermectin vs placebo Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical ivermectin vs placebo Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 1371 participants | High |
Topical ivermectin vs placebo Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 1371 participants | High |
Topical ivermectin vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical brimonidine vs vehicle HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical brimonidine vs vehicle Participant‐assessed improvement in rosacea severity Patient Satisfaction Assessment ‐ grade 2 improvement · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 553 participants | High |
Topical brimonidine vs vehicle Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 553 participants | High |
Topical brimonidine vs vehicle Physician‐assessed improvement in rosacea severity ‐ not reported · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical brimonidine vs vehicle Assessment of erythema or telangiectasia Clinician Erythema Assessment ‐ grade 2 improvement · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 553 participants | High |
Metronidazole vs placebo Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.19 [0.94, 1.51] | 6 studies · 1773 participants | High |
Topical brimonidine vs vehicle Lesion count ‐ not reported · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical brimonidine vs vehicle Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 553 participants | High |
Topical brimonidine vs vehicle Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical azelaic acid vs topical metronidazole HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical azelaic acid vs topical metronidazole Participant‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 491 participants | Low |
Topical azelaic acid vs topical metronidazole Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 491 participants | Low |
Topical azelaic acid vs topical metronidazole Physician‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 491 participants | Low |
Topical azelaic acid vs topical metronidazole Assessment of erythema or telangiectasia · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 491 participants | Low |
Topical azelaic acid vs topical metronidazole Lesion counts · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 491 participants | Moderate |
Topical azelaic acid vs topical metronidazole Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 3 studies · 491 participants | Ungraded |
Metronidazole vs placebo Physician‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.98 [1.29, 3.02] | 3 studies · 334 participants | Moderate |
Topical azelaic acid vs topical metronidazole Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical ivermectin vs topical metronidazole HRQOL DLQI, proportion of participants that reported at end of study that rosacea had no impact on QoL · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.11 [1.01, 1.21] | 1 study · 962 participants | High |
Topical ivermectin vs topical metronidazole Participant‐assessed improvement in rosacea severity Likert scale ‐ good to excellent improvement · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.14 [1.07, 1.22] | 1 study · 962 participants | High |
Topical ivermectin vs topical metronidazole Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 2.28 [0.71, 7.35] | 1 study · 962 participants | Moderate |
Topical ivermectin vs topical metronidazole Physician‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.13 [1.06, 1.2] | 1 study · 962 participants | High |
Topical ivermectin vs topical metronidazole Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Topical ivermectin vs topical metronidazole Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 962 participants | High |
Topical ivermectin vs topical metronidazole Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 962 participants | High |
Topical ivermectin vs topical metronidazole Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears HRQOL Ocular Surface Disease Index (scale 0 to 100, 100 worst) · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |